Emerson Perin, MD, PhD FACC

Director, Clinical Research for Cardiovascular Medicine
Medical Director of the Stem Cell Center
Texas Heart Institute
Staff Interventional Cardiologist at St. Luke’s Episcopal Hospital
Clinical Assistant Professor of Internal Medicine
Baylor College of Medicine and The University of Texas Health Science Center at Houston
(Houston, Texas)

Dr. Perin is the Director of Clinical Research for Cardiovascular Medicine and the Medical Director of the Stem Cell Center at the Texas Heart Institute at St. Luke’s Episcopal Hospital, as well as the Staff Interventional Cardiologist at St. Luke’s Episcopal Hospital. He is also Clinical Assistant Professor of Internal Medicine both at Baylor College of Medicine and The University of Texas Health Science Center at Houston.

Dr. Perin has provided innovative cardiovascular care for 20 years, focusing on minimally invasive interventional approaches to therapy. For more than 10 years, his major research interest has been the study of adult stem cells for the treatment of acute myocardial infarction, chronic heart failure, and peripheral vascular disease.

Dr. Perin’s specialty interests include leading-edge interventional cardiology including transmyocardial laser revascularization, angiogenesis, and biosense mapping. He was the first investigator in the United States to receive approval from the Food and Drug Administration to inject stem cells directly into the hearts of patients suffering from heart failure.

Scientists and physicians in THI’s Stem Cell Center, in addition to focusing on clinical trials, are among the leaders in performing basic science and translational (preclinical) research to advance stem cell therapy for treating heart and vascular disorders. THI’s Stem Cell Center was one of only five sites designated by the National Institutes of Health for stem cell treatment of cardiovascular disease as part of the Cardiovascular Cell Therapy Research Network and is one of four centers renewed as part of a seven center CCTRN network funded for seven additional years.